Diagnosis & Disease Information

Molecular testing may be underused in patients with metastatic NSCLC and may delay the start of systemic therapy, a study suggests.

Adding ipilimumab to nivolumab and chemotherapy improves responses in patients with operable non-small cell lung cancer, a phase 2 trial suggests.

Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.

The risk of hyperprogression is lower when atezolizumab is given upfront to patients with advanced non-small cell lung cancer, a study suggests.

A phase 2 trial suggests that frontline osimertinib and platinum-based chemotherapy is safe and effective in EGFR-mutated, advanced NSCLC.

Five-year data support the use of pembrolizumab plus pemetrexed-platinum chemotherapy as standard care for previously untreated, metastatic, EGFR/ALK-wild-type NSCLC, according to researchers.

Adding chemotherapy to first-line treatment with gefitinib improves outcomes in patients who have EGFR-mutant non-small cell lung cancer with brain metastases, a phase 3 trial suggests.

Adding pembrolizumab to chemotherapy nearly doubles the 5-year overall survival rate in patients with advanced non-small cell lung cancer, phase 3 data suggest.

Lobectomy and sublobar resection produce similar outcomes in patients with T1aN0 non-small cell lung cancer, a phase 3 study suggests.